Vertex Pharmaceuticals Incorporated Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.5%projected annual EPS growth
Analyst Coverage
25analysts covering
FY Revenue (est.)
$13.2Bnext fiscal year
FY EPS (est.)
$19.05next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Next Earnings Release | 2 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly total revenue in USD billions Quarterly3.3
Povetacicept RAINIER Week 36 UPCR reduction versus placebo in percent Quarterly0.5
Watch Items
- Povetacicept FDA decision for accelerated approval in IgA nephropathyAction: Reassess the nephrology growth thesis, launch timing, and probability assigned to the bull and base cases.
- Completion of the planned Crinetics Pharmaceuticals acquisitionAction: Review regulatory, financing, integration, and pipeline implications if the transaction does not close in the announced period.
Research as of 29 Aug 2026